Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Teva
Merck
Colorcon
Cerilliant
Boehringer Ingelheim
Medtronic
Argus Health
US Army
Fish and Richardson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022502

« Back to Dashboard

NDA 022502 describes DIFFERIN, which is a drug marketed by Galderma Labs Lp and is included in five NDAs. It is available from eight suppliers. There are nine patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DIFFERIN profile page.

The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the adapalene profile page.
Summary for 022502
Tradename:DIFFERIN
Applicant:Galderma Labs Lp
Ingredient:adapalene
Patents:3
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 022502
Ingredient-typeRetinoids
Medical Subject Heading (MeSH) Categories for 022502
Suppliers and Packaging for NDA: 022502
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIFFERIN adapalene LOTION;TOPICAL 022502 NDA Galderma Laboratories, L.P. 0299-5912 0299-5912-01 15 mL in 1 BOTTLE (0299-5912-01)
DIFFERIN adapalene LOTION;TOPICAL 022502 NDA Galderma Laboratories, L.P. 0299-5912 0299-5912-02 1 BOTTLE, PUMP in 1 CARTON (0299-5912-02) > 59 mL in 1 BOTTLE, PUMP

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:LOTION;TOPICALStrength0.1%
Approval Date:Mar 17, 2010TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:May 31, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE
Patent:➤ SubscribePatent Expiration:Sep 15, 2026Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE
Patent:➤ SubscribePatent Expiration:Sep 15, 2026Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Merck
Dow
Fish and Richardson
Healthtrust
Novartis
Cerilliant
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot